The Clinical Observation of First-Line Docetaxel and Carboplatin Treatment for Elderly Patients with Non-Selective Non-Small-Cell Lung Cancer
January 2012
in “
Journal of Clinical Medicine in Practice
”
Studysummary This study found that first-line treatment with docetaxel and carboplatin was safe and effective for elderly patients with advanced non-selective non-small-cell lung cancer, showing an overall efficacy rate of 47.87%.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study observed the efficacy and toxicity of first-line docetaxel and carboplatin treatment in 46 elderly patients with advanced non-selective non-small-cell lung cancer (NSCLC). The treatment regimen involved docetaxel at 60 mg/m² on day 1 and carboplatin with an AUC of 4 on day 2, repeated every 21-28 days for at least 2 cycles. Results showed a complete remission in 1 patient, partial remission in 21 patients, stable disease in 19 patients, and disease progression in 5 patients, leading to an overall efficacy rate of 47.87%. The median time to progression was 5.61 months, with a median survival time of 13.21 months and a 1-year survival rate of 49.21%. The main side effects included leukopenia, bone and joint pain, finger numbness, and hair loss, which were manageable with active treatment. The study concluded that this treatment was safe and effective for advanced non-selective NSCLC in elderly patients.
